mylan-makes-major-pharma-acquisition-in-india

Mylan makes major pharma acquisition in India

NYSE-listed Mylan Laboratories to acquire 71.5% of IndiaÆs Matrix Laboratories for a maximum price of $736 million in deal in which private equity investors in Matrix Laboratories will take a stake in acquirer, Mylan.
NYSE listed Mylan Laboratories Mylan announced on August 28 that it will acquire 71.5% of IndiaÆs Matrix Laboratories for a maximum price of $736 million. The transaction has been structured in a way that part of the gains realised by the private equity firms on their investment in Matrix Laboratories will be reinvested in acquirer, Mylan. The deal values Matrix at $1.03 billion and represents a 22 times earnings multiple. The transaction is one of the largest to date for India's pharmaceutical industry.

The transaction will be effected through the purchase of 51.5% of Matrix shares through a negotiated agreement with the private equity firms and an open offer, pursuant to IndiaÆs takeover code, for...
¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222